The prevalence of type 2 diabetes mellitus and insulin resistance are higher among people chronically infected with hepatitis C (CHC) when compared with the general population and people with other causes of chronic liver disease. Both insulin resistance and diabetes are associated with adverse outcomes across all stages of CHC, including the liver transplant population. CHC is also associated with the development of hepatic steatosis, a common histological feature present in approximately 55% (3281%) of cases. There is a complex interrelationship between insulin resistance and hepatic steatosis and both are postulated to aggravate each other. The peroxisome proliferator-activated receptors (PPARs) are nuclear factors involved in the regulation of glucose, lipid homeostasis, inflammatory response, cell differentiation, and cell cycle. The relationship between hepatitis C virus replication and PPARs has been the focus of recent study. Given the availability of potent agonists, PPARs may represent a novel pharmacological target in the treatment of CHC.
Introduction
Chronic hepatitis C virus (CHC) infects approximately 170 million people worldwide, and is a major cause of mortality and morbidity [WHO, 2009] . The natural history of HCV infection is characterized by a high rate of progression to chronic hepatitis leading to cirrhosis in approximately 20% of cases and possibly to hepatocellular carcinoma [Seeff, 2009] . In addition to progressive liver disease, CHC has been linked to dysregulated energy metabolism to include insulin resistance (IR), type 2 diabetes mellitus (T2DM), hepatic steatosis and increased risk of carotid atherosclerosis [Koike, 2009; Negro and Sanyal, 2009; Romero-Gó mez, 2006] . This is due, in part, to a direct interference of HCV with lipid and glucose metabolism and a complex relationship between IR and steatosis in patients with CHC. The mechanisms involved seem to be HCV genotype specific [Moucari et al. 2008; Pazienza et al. 2007 ]. Since the peroxisome proliferator-activated receptors (PPARs) are nuclear factors involved in the regulation of glucose and lipid homeostasis, the relationship between HCV replication and protein expression and PPARs has been the focus of recent study. This review first describes the main function of PPARs within the liver, the interaction between PPARs and HCV, and then its potential role in HCV pathophysiology and therapy is discussed.
Peroxisome proliferator-activated receptors PPARs belong to the nuclear receptor superfamily and require heterodimerization with receptor X for retinoids (RXR) in order to function [Desvergne and Wahli, 1999; Bardot et al. 1993 ]. The PPAR:RXR heterodimer, when bound to a ligand, changes conformation and binds to DNA at PPAR response elements, resulting in gene transcription [Bardot et al. 1993; Gearing et al. 1993] . PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein) , and tumorigenesis [Desvergne and Wahli, 1999; Bardot et al. 1993 ].
There are three isotypes of PPAR designated in mammals: PPARa (NR1C1), PPARd (NR1C2) and PPARg (NR1C3) [Nuclear Receptors Nomenclature Committee, 1999] . PPARa is activated by ligands termed peroxisome proliferators, which were named for their effects on peroxisomes in rodent livers [Svoboda and Azarnoff, 1966; Hess et al. 1965] .
PPARa/g, together with their obligate partner RXR, are the main nuclear receptors expressed in the liver. These receptors contribute to important physiological processes occurring in the liver to include control of lipid and glucose metabolism, inflammatory responses, and cellular differentiation and proliferation. The availability of new nonhepatotoxic ligands made it possible to evaluate certain PPARs as potential new therapeutic targets in liver disease.
PPARs and insulin resistance and diabetes
PPARs play an essential role in glucose homeostasis. PPARa upregulates glycerol-3-phosphate dehydrogenase, glycerol kinase and glycerol transport proteins, which allows for glucose synthesis during fasting states [Patsouris et al. 2004] . PPARa also stimulates pancreatic islet ß cells, increasing fatty acid oxidation and potentiating glucose-stimulated insulin secretion [Lefebvre et al. 2006 ]. In addition, PPARs possess insulinsensitizing effects which lead to decreased ß-cell workload. This is particularly beneficial for ß-cell survival and prevention of pancreatic degradation.
In a recent randomized controlled trial the diabetic patients from the placebo group demonstrated a progressive decline in homeostatic indices of ß-cell function and an increase in IR was calculated according to the homeostasis model of assessment (HOMA) over 2 years of follow up. These longitudinal changes were attenuated by the PPARa ligand bezafibrate [Tenenbaum et al. 2007 ].
For PPAR, clinical data demonstrated that the PPAR agonists (thiazolidinediones such as pioglitazone) improve hyperglycaemia and hyperlipidaemia in obese and diabetic animals through reduction of both peripheral and hepatic IR [Jay and Ren, 2007] .
The mechanisms of PPAR-mediated insulin sensitization are complex and are thought to involve specific effects on fat, skeletal muscle, and liver ( Figure 1 ). Specifically, PPARgs:
1. Increase glucose catabolism and decrease hepatic glucose output [Nagashima et al. 2005; Sakamoto et al. 2005 ). 2. Increase GLUT4 expression and translocation in adipocytes [Armoni et al. 2003 ].
3. Lead to adipose remodeling. This phenomenon may explain the 'fatty acid steal' hypothesis [Berthiaume et al. 2004 ]. 4. Increase expression of adipocytokines such as adiponectin, which may stimulate fatty acid oxidation in skeletal muscle and liver [Pajvani et al. 2004 ]. 5. Increase glucose uptake in skeletal muscle resulting in lower blood glucose levels [Le Brasseur et al. 2006 ]. 6. Impact directly on factors involved in lipid and glucose homeostasis. 7. May have insulin-sensitizing effects via their anti-inflammatory activity.
Thus, treatment with PPARg agonists results in improved insulin sensitivity via diverse mechanisms, both direct and indirect, and at the level of the liver and other extrahepatic tissues.
PPARs and lipid metabolism
The liver is the central organ responsible for fat metabolism and lipid homeostasis [Everett et al. 2000 ]. It is involved in free fatty acid synthesis, esterification of triacylglycerols and their packaging into very low-density lipoproteins (VLDLs) for exportation during the fed state [Everett et al. 2000 ]. During the fasted state, the liver is responsible for controlling the rates of fatty acid ß-oxidation and ketogenesis. The liver maintains lipid homeostasis by balancing these processes.
PPARa is a key mediator in maintaining this balance Nakamura et al. 2004; Hertz et al. 1995] by acting as a sensor for the level of free fatty acids and modulating the responses of fat-oxidizing tissues [Everett et al. 2000 ].
PPARa is activated by dietary fatty acids and eicosanoids or by specific drugs such as the fibrates. Activation of PPARa results in an increase in the enzymes involved in lipid metabolism and fatty acid ß-oxidation. Loss of expression of the PPARa gene in mice results in hepatic steatosis under conditions of increased fatty acid metabolism in the liver, such as fasting or a highfat diet [Kersten et al. 1999; Lee et al. 1995] . Administration of a potent PPARa agonist decreases hepatic steatosis in mice receiving a methionine and choline deficient diet [Nagasawa et al. 2006 ].
Intracellular fatty acid concentrations are controlled, in part, by regulation of the fatty acid import and export system. Activation of PPARa directly regulates genes involved in fatty acid uptake [Escher and Wahli, 2000] . Also, both PPARa and PPARg prevent the efflux of fatty acids by promoting their activation into fatty acyl CoA thioesters by the acyl-CoA synthetase [Hsu et al. 2001 ].
In addition, PPARa activation regulates hepatic triglyceride content by promoting fatty acid oxidation in peroxisomes and in the mitochondria, and reducing the fatty acid pool available to the liver for triglyceride synthesis [Latruffe et al. 2000] ; enhancing lipoprotein lipase expression [Schoonjans et al. 1996] ; and inhibiting apolipoprotein C-III in the liver [Staels et al. 1995] ( Figure 2 ).
Adiponectin, an adipocyte produced peptide hormone, limits fat accumulation in the liver by a number of mechanisms including activation of PPARa to increase hepatic fatty acid oxidation [Yamauchi et al. 2003 ]. Adiponectin is upregulated by PPARg, providing a connection between the two isotypes [Neschen et al. 2006] (Figure 2 ).
PPARg is highly expressed in adipose tissue under two isoforms (PPARg1 and PPARg2) generated by the same gene through altered splicing [Fajas et al. 1997 ] and they have a complementary role in lipid homeostasis. PPARg mediates its effect on lipid homeostasis by dual action: its role in increasing insulin sensitivity, and its effect on adipocytes.
PPARg plays an important role in control of hepatic steatosis by increasing insulin sensitivity (see above). IR is integral to the development of nonalcoholic fatty liver disease (NAFLD), leading to increased fatty acid flux to the liver and increased hepatic fatty acid synthesis [Yu and Ginsberg, 2005] .
Alternatively, PPARg mediates its effect on adipocytes by promoting fatty acid uptake into adipocytes, adipocyte differentiation [Schoonjans , 1999] and synthesis [Frohnert et al. 1999] . The net effect of these processes is to increase triglyceride storage in adipocytes, reducing delivery of fatty acids to the liver. Patients with dominant negative mutations in PPARg have NAFLD and metabolic syndrome, while lacking adipose tissue, suggesting increased triglyceride delivery to the liver [Savage et al. 2003 ].
PPARg is also involved in the induction of uncoupling protein-2, which might decrease hepatic triglyceride accumulation by increasing energy expenditure [Castelein et al. 1994] .
PPAR: anti-inflammatory and immunomodulatory properties in the liver
In addition to the lipid-lowering and insulinsensitizing effects of the PPAR ligands, there are numerous experimental and clinical data in favor of the anti-inflammatory activity of PPARs in the liver.
Evidence has demonstrated the effects of an RXR agonist and a PPARg agonist on tumor necrosis factor-a (TNF-a) production [Uchimura et al. 2001] . PPARg:RXR activation suppresses nuclear factor kappa B, signal transducers and activators of transcription, activating protein 1 signalling pathways and TNF-a production in Kupffer cells in primary hepatocyte cultures and monocytes/macrophages. PPARa can also control hepatic inflammation by regulating hemostatic factors, acute-phase response proteins in hepatocytes [Anderson et al. 2002] , and regulating antioxidant enzyme activities, such as catalase. In addition, PPARa agonists may reduce the oxidative stress [Hashimoto et al. 2000 ].
Hepatitis C virus and insulin resistance
The prevalence of both IR and T2DM is significantly higher in patients with CHC when compared with other chronic liver diseases [Romero-Gó mez et al. 2005; Hui et al. 2003; Caronia et al. 1999; Mason et al. 1999; Grimbert et al. 1996; Allison et al. 1994 ]. The prevalence of diabetes in patients with chronic hepatitis has ranged from 20% to 50% [Moucari et al. 2008; Caronia et al. 1999; Grimbert et al. 1996] . This is higher than that reported for patients with other chronic liver diseases such as chronic hepatitis B, independent of the stage of liver fibrosis [Romero-Gó mez et al.
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This association between diabetes and CHC was first reported by Allison and colleagues [Allison et al. 1994] , who observed that diabetes was significantly more prevalent in patients with hepatitis Crelated cirrhosis than those with cirrhosis resulting from conditions other than CHC (50% versus 9%). Since then, a number of cross-sectional, case control, and longitudinal studies, performed in both large unselected cohorts and in patients with liver or kidney transplantation, have re-affirmed this association. Hui and colleagues [Hui et al. 2003] found that 121 patients with HCV and stage 0 or 1 liver fibrosis had higher HOMA scores compared with 137 healthy volunteers matched by sex, body mass index, and waist-to-hip ratio. This work proved that HCV may induce IR at early stages of liver disease. Another classic way to prove an association between infection and disease comes from the fact that curing HCV results in improvement in the HOMA score and a decreased incidence of T2D after cessation of therapy [Chehadeh et al. 2009; Romero-Gó mez et al. 2008; Kawaguchi et al. 2007 ].
The mechanisms of IR in CHC are an area of intense study, and numerous molecular pathways have been implicated. IR in CHC arises both as a direct consequence of the virus and indirectly as a consequence of lipid accumulation and/or inflammation. HCV seems to lead to IR through interference of intracellular insulin signalling by HCV proteins, mainly the serine phosphorylation of IRS-1 and impairment of the downstream Akt signaling pathway. Also, HCV core protein inhibits PPARa and PPARg expressed in hepatocytes and adipocytes promoting insulin receptor substrates-1 (IRS-1) degradation and IR. The HCV core protein interferes with in vitro insulin signaling by genotype-specific mechanisms [Moucari et al. 2008; Pazienza et al. 2007 ]. Moucari and colleagues found genotypes 1 and 4 to be correlated independently with IR [Moucari et al. 2008 ]. The rationale is unclear and may be based on the known differences in treatment response between these groups rather than interactions between viral proteins and host signaling pathways.
While CHC is independently associated with IR and T2DM, the presence of concomitant hostspecific risk factors also contributes to both the prevalence and the degree of disturbance of glucose homeostasis in a complex interrelationship between these factors in CHC.
The association between HCV and IR has noteworthy consequences, clinically and conceptually. From the clinical standpoint, IR accelerates fibrogenesis [Hui et al. 2003 ], impairs early and sustained virologic response (SVR) to interferonbased antiviral therapy Mizuta et al. 2010; Chu et al. 2009; Dai et al. 2009; Poustchi et al. 2008; Conjeevaram et al. 2007; Romero-Gómez et al. 2005] (Figure 3) , and increases the incidence of hepatocellular carcinoma [Pekow et al. 2007 ].
Hepatitis C virus and fatty liver
The prevalence of steatosis in patients with CHC is reported to be between 40% and 80% depending on the features of the population studied in terms of alcohol consumption, prevalence of overweight/obesity, diabetes and other risk factors of fatty liver [Asselah et al. 2005] . However, when all common factors of steatosis have been ruled out, the prevalence of steatosis in CHC remains about 40%. This figure represents an approximately twofold increase compared with the prevalence of steatosis in other common chronic liver diseases such as hepatitis B (20%) [Thomopoulos et al. 2006; Rubbia-Brandt et al. 2000 ]. This suggests that hepatitis C virus (HCV) may directly cause fatty liver, at least in subgroups of patients with CHC.
Steatosis appears to be a direct consequence of viral protein expression in genotype 3 infection, suggesting the presence of specific sequences across the genome of genotype 3 that are involved in fat accumulation within hepatocytes. With other genotypes, steatosis is associated with features of the metabolic syndrome to include IR and obesity [Negro and Sanyal, 2009] . This is further supported by two additional observations. First, the severity of steatosis correlates with the level of HCV RNA, both in liver [Rubbia-Brandt et al. 2000 ] and in serum [Adinolfi et al. 2001] , especially in patients with genotype 3. Second, fatty liver may significantly decrease, if not disappear altogether, when patients are successfully treated with antiviral agents. Again, this is most pronounced in patients infected with genotype 3 virus [Poynard et al. 2003; Rubbia-Brandt et al. 2000 ]. Steatosis may persist in most patients with non-3 genotypes, even in the case of sustained virologic response [Poynard et al. 2003 ]. A relapse after the end of therapy may result in the reappearance of steatosis in patients in whom it had disappeared while on treatment [Rubbia-Brandt et al. 2001 ].
The composition of fatty acids that are accumulated in the liver of core gene transgenic mice is different from that in fatty liver due to simple obesity. Carbon-18 monounsaturated fatty acids (C18: 1) such as oleic or vaccenic acids are significantly increased. This is also the case in the comparison of liver tissues from patients with CV and those with simple fatty liver due to obesity [Moriya et al. 2001 ].
Recent studies have attempted to explain the potential mechanisms underlying the steatosis often seen in patients with CHC. In general, HCV may interfere with lipid metabolism at three levels: impaired secretion, impaired degradation and increased neolipogenesis. Impaired secretion of lipoproteins from the infected hepatocyte was the first proposed mechanism of HCV-induced steatosis. Data suggest that HCV core protein may cause hepatic steatosis through inhibition of microsomal triglyceride transfer protein (MTP) activity [Perlemuter et al. 2002] because this enzyme plays a key ratelimiting role in very-low-density lipoprotein assembly. This inhibits the secretion of VLDL consisting of apolipoprotein B, cholesterol and triglycerides from the liver. The findings of impaired MTP functioning as a result of HCV core protein expression have more recently been extended to humans. In a study of 58 patients infected with various HCV genotypes, a highly significant (p ¼ 0.0017), inverse correlation was found for liver MTP mRNA levels and the degree of hepatic steatosis that was independent of genotype, suggesting an important role for MTP in hepatic steatosis [Mirandola et al. 2006 ].
HCV may also cause steatosis by decreasing fatty acid oxidation through impairment of the expression and transcriptional activity of PPARa which regulates several genes responsible for fatty acid degradation [Cheng et al. 2005 ] (see below).
HCV may induce fatty liver by stimulating de novo synthesis of fatty acids. During primary infection in chimpanzees, HCV activates genes involved in lipid metabolism via upregulation of sterol regulatory element binding protein-1c (SREBP) [Waris et al. 2007; Su et al. 2002] . SREBP activity is stimulated in vitro by several viral proteins, including core [Waris et al. 2007] and nonstructural proteins 2 [Oem et al. 2008] and 4B [Park et al. 2009; Oem et al. 2008; Waris et al. 2007 ]. Activation of SREBP and several enzymes involved in lipidogenesis has also been reported in transgenic mice expressing different HCV proteins [Lerat et al. 2009; Chang et al. 2008 ]. In addition to activating SREBP, the HCV core protein may also bind to and activate the DNA-binding domain of the retinoid receptor a, a transcriptional regulator that controls many cellular functions including cellular lipid synthesis [Fukasawa et al. 2006 ].
Finally, an additional mechanism leading to fatty liver may be related to the increased prevalence of IR among patients with CHC. IR increases the peripheral release and hepatic uptake of fatty acids, resulting in an accumulation of lipid in the liver [Browning and Horton, 2004] . Although HCV may be associated with extrahepatic IR [Milner et al. 2010; Vanni et al. 2009 ], this seems to involve striated muscles rather than the adipose tissue. Thus, there is no evidence as yet that HCV may induce fatty liver via increased lipolysis in adipocytes.
Insulin resistance and steatosis: the chicken and the egg relationship
Although both IR and steatosis are common findings in patients with CHC, what comes first is not entirely clear. In the absence of HCV infection, much of the cardiovascular and endocrine literature has attributed IR to the presence of excessive triglyceride in organs such as the liver and muscle [den Boer et al. 2004; Ryysy et al. 2000] . By contrast, accumulating data seem to indicate that rather than causing IR, the presence of visible hepatocyte triglyceride droplets is a consequence of IR, hyperinsulinemia, and the result of excessive flux of free fatty acids through the liver [Monetti et al. 2007; Buettner et al. 2004] .
Moreover, it is still unclear if hepatic steatosis represents the first hit to proinflammatory cytokine production which then leads to the development of IR or vice versa. Recent evidence, discriminating between 'systemic' and 'hepatic' IR, shows that in young, lean, patients with IR there was a low prevalence of hepatic steatosis and no cytokine/adipocytokine changes. This suggests that steatosis and cytokines interact without assuming a primary and independent role in the early stage of IR [Petersen et al. 2007] . Alternatively, other authors support the idea that hyperinsulinemia is likely to be the consequence rather than the cause of a fatty liver, as suggested by the fact that fatty liver is associated with both hepatic IR and impaired insulin clearance [Harsha and Bray, 2008; Hickman et al. 2004 ].
In patients with CHC, the HCV virus seems to play an additive role in this complex and reciprocal relationship as evidenced by the accumulating evidence of a direct 'metabolic' effect of the HCV virus on a large number of molecular pathways that lead to hepatic steatosis, IR and metabolic syndrome [Sheikh et al. 2008; Eckel et al. 2005] . Whereas core proteins from all HCV genotypes appear to influence this relationship, genotypespecific mechanisms may account for these effects, and although selected genotypes (e.g. 3a) may be more efficient in promoting hepatic steatosis, triglyceride droplets may be inert with respect to promoting injury and altered cellular homeostasis. In this case fat accumulation does not in itself precipitate IR and those patients who are IR typically have other causes such as obesity [Hui et al. 2003 ].
Preexisting metabolic conditions such as metabolic syndrome can also contribute to IR and steatosis in patients with HCV. In a study of 271 patients without diabetes, liver fat was four times higher in patients with metabolic syndrome (median 8.2%) compared with those without metabolic syndrome (median 2.0%; p ¼ 0.0001), and this difference remained significant when adjusted for age, gender and body mass index (BMI) (p ¼ 0.011) [Kotronen et al. 2007 ]. Among patients with metabolic syndrome in this study, liver fat was progressively increased (p ¼ 0.0001 for trend) in patients as the number of components of metabolic syndrome increased. Patients with metabolic syndrome also had significantly higher fasting serum insulin and C-peptide concentrations than those without metabolic syndrome independent of age, gender and BMI (fasting serum insulin adjusted r ¼ 0.39, p ¼ 0.0001; C-peptide adjusted r ¼ 0.36, p ¼ 0.0001) [Kotronen et al. 2007 ]. Thus, this study suggests that liver fat content is an important component of the metabolic syndrome and increases proportionally with the number of components of the metabolic syndrome. Moreover, of all measures of IR, fasting serum insulin and C-peptide were the best correlates of liver fat [Kotronen et al. 2007 ]. These findings, taken together, suggest a definite genotypic association between the IR and steatosis/steatohepatitis with HCV as the 'third player'. However, to further refine the nature of this interaction more investigation of the genotypic specificity of the virushost interaction is needed.
Interaction between hepatitis C and PPARs
The interaction between HCV products and PPAR expression has been an area of recent focus. Liver inflammation, hepatocyte fat accumulation, and diabetes are three pivotal hallmarks in the natural history of CHC infection which are at least in part controlled by PPARs.
Expression of PPARa appears to be impaired with HCV infection [de Gottardi et al. 2006; Dharancy et al. 2005] . In patients with CHC, expression of the PPARa gene in the liver was reduced by 86% compared with controls, and the expression of its target gene, CPT1A, was coordinately reduced by 85%. Thus, hepatocytes infected with HCV display abnormally low levels of PPARa. Alternatively, PPAR, RXR and liver X receptor were not different. Similarly, expression of the core protein in hepatoma cells was also found to reduce PPARa levels, but not the expression of the aforementioned receptors, and the induced expression of the CPT1A target gene by fenofibric acid was inhibited in core proteinexpressing cells but not control cells [Dharancy et al. 2005] .
Recent evidence of a direct role for PPARa activation in the pathogenesis of steatosis and HCC has been obtained from studies that combined core gene transgenic mice with PPARa knockout (KO) mice. The results of these experiments found that PPARa KO mice have reduced expression of target genes of PPARa, and have mild steatosis in the liver as expected [Tanaka et al. 2008] . Steatosis and hepatocellular carcinoma developed in PPARa intact but not in PPARa heterozygous or PPARa null core gene transgenic mice, indicating that not the presence but the persistent activation of PPARa would be important in hepatocarcinogenesis by HCV core protein. In general, PPARa acts to ameliorate steatosis, but with the presence of mitochondrial dysfunction, which is also provoked by the core protein, the core activated PPARa may exacerbate steatosis. This study showed that expression of the core protein in and of itself was insufficient to cause steatosis, as evidenced by the lack of steatosis in mice heterozygous or homozygous for the deletion of PPARa. A persistent activation of PPARa with 'strong' ligands such as the core protein of HCV could be carcinogenic in humans, although the low-affinity fibrate ligands are not likely associated with human cancers [Tanaka et al. 2008] .
Others have shown that PPAR expression is significantly lower in genotype 3 compared with genotype 1 HCV infection and that steatosis is associated with decreased levels of PPAR in genotype 1 HCV infection [de Gottardi et al. 2006] . In this study, there was no significant relationship between the PPARs mRNA levels and liver activity or fibrosis. The presence of steatosis and HCV genotype 3 were both associated with a significant downregulation of PPARs.
Perspectives for treatment
Although, increasing insulin sensitivity may be a rationale option in patients with CHC, especially those with metabolic syndrome, the modalities for this intervention have not been established yet. The primary data on the use of pioglitazone (PIO) was from a prospective, multicenter study aimed at investigating the efficacy and safety of PIO, 15 mg daily, added to pegylated interferon-2a (Peg-IFN-2a), 180 g every week and ribavirin (RBV) 10001200 mg daily combination therapy in retreatment of patients with CHC who were previously nonresponders to a Peg-IFN-a/RBV combination. All patients were IR and had a baseline HOMA > 2 [Overbeck et al. 2008 ].
The study was prematurely terminated as none of the first five patients enrolled into the trial had a sufficient virological response after 12 weeks. The dose of PIO used in this study was quite low, however, and may have impacted on the results [Negro, 2009] . The following emerging data from the four available studies evaluating the use of PIO in addition to the Peg-IFN a/ RBV combination is provocative Vierling et al. 2010; Conjeevaram et al. 2008; Elgouhari et al. 2008] . In one study of treatment-naïve, non-diabetic, genotype 1 patients, 30 mg/day of PIO was given for 4 weeks as monotherapy and then added for the first 4 weeks of a standard therapy. The authors showed that the triple regimen increased the rate of virological response significantly after 4 weeks of therapy compared with the standard of care. Long-term data from this study is keenly awaited [Elgouhari et al. 2008] . In another randomized, double-blind, placebo-controlled study in genotype 1 patients, adding PIO 30 mg/day simultaneously to the standard of care (i.e. without preceding administration as monotherapy) clearly improved IR, steatosis and increased the on-treatment virological response but failed to increase the SVR [Conjeevaram et al. 2008 ]. The third trial was conducted conclusively in patients infected with HCV genotype 4. The use of PIO 30 mg/day simultaneously with the standard antiviral therapy increased rapid virologic response (RVR) and SVR rates with improvement in all parameters of IR .
Results from another study were previously presented at the 2010 meeting of the American Association for the Study of Liver Disease. The sequential use of PIO for 16 weeks (30 mg/ day Â 8 weeks then 45 mg/day Â 8 weeks) prior to and concordant with 48 weeks of standard of care therapy revealed improvements in several glycemic variables, but no improvement in RVR or early virologic response (EVR) was seen. Data on SVR were not available [Vierling et al. 2010] .
The final answer as to whether improving IR with thiazolidinedione therapy such as PIO equates to improved virologic response remains unknown at the current time. It is possible that there may be genotypic variations in response. In addition, genetic and epigenetic influences, such as IL28B single nucleotide polymorphisms, may be associated with IR and despite improvement in IR enhancement in SVR may not be seen. Clinical trials are underway seeking answers to these questions and the data are eagerly anticipated. 
